Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain - PubMed

Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain

B Kaplan et al. Am J Kidney Dis. 1999 Jul.

Abstract

Abdominal pain occurs frequently in renal transplant recipients receiving mycophenolate mofetil (MMF) therapy. The cause of this abdominal pain has not been fully elucidated, but may involve local irritation, as well as inhibition of rapidly dividing cells of the gastrointestinal (GI) tract. This milieu of inflammation and added immunosuppression is conducive to activation of cytomegalovirus (CMV). We therefore sought to find the prevalence of active CMV in patients presenting with abdominal pain on maintenance MMF therapy. All patients receiving a renal transplant at our center from March 1, 1997, to September 1, 1997, were studied. Any patient presenting with midepigastric pain for greater than 3 days underwent esophagogastroduodenoscopy (EGD) with biopsy. CMV was diagnosed by the presence of inclusion bodies and immunohistochemical studies. Ten patients presented with persistent midepigastric pain; nine of these patients had evidence of GI CMV. Patients who were CMV negative and received an allograft from CMV-positive donors and those with leukopenia were at significantly increased risk for the development of abdominal pain. In our study population, the majority of patients on maintenance MMF therapy who presented with persistent midepigastric pain had evidence of active CMV infection in the upper gastrointestinal tract.

Similar articles

• Cytomegalovirus infection and abdominal pain with mycophenolate mofetil: is there a link?

  Gallagher H, Andrews PA. Gallagher H, et al. Drug Saf. 2001;24(6):405-12. doi: 10.2165/00002018-200124060-00001. Drug Saf. 2001. PMID: 11368249 Review.

• Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.

  Bataille S, Moal V, Gaudart J, Indreies M, Purgus R, Dussol B, Zandotti C, Berland Y, Vacher-Coponat H. Bataille S, et al. Transpl Infect Dis. 2010 Dec;12(6):480-8. doi: 10.1111/j.1399-3062.2010.00533.x. Transpl Infect Dis. 2010. PMID: 20629971 Clinical Trial.

• Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.

  Viganò M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E, Kleinloog R, Li Y, Gezahegen Y, Delgado JF; RAD A2411 Study Investigators. Viganò M, et al. Transpl Infect Dis. 2010 Feb;12(1):23-30. doi: 10.1111/j.1399-3062.2009.00448.x. Epub 2009 Sep 9. Transpl Infect Dis. 2010. PMID: 19744284 Clinical Trial.

• Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients?--A mini-review.

  Song AT, Abdala E, Bonazzi PR, Bacchella T, Machado MC. Song AT, et al. Braz J Infect Dis. 2006 Apr;10(2):132-8. doi: 10.1590/s1413-86702006000200011. Braz J Infect Dis. 2006. PMID: 16878265 Review.

• Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses.

  Moreso F, Serón D, Morales JM, Cruzado JM, Gil-Vernet S, Pérez JL, Fulladosa X, Andrés A, Grinyó JM. Moreso F, et al. Clin Transplant. 1998 Jun;12(3):198-205. Clin Transplant. 1998. PMID: 9642510 Clinical Trial.

Cited by

• Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management.

  Behrend M. Behrend M. Drug Saf. 2001;24(9):645-63. doi: 10.2165/00002018-200124090-00002. Drug Saf. 2001. PMID: 11522119 Review.

• Cytomegalovirus infection and abdominal pain with mycophenolate mofetil: is there a link?

  Gallagher H, Andrews PA. Gallagher H, et al. Drug Saf. 2001;24(6):405-12. doi: 10.2165/00002018-200124060-00001. Drug Saf. 2001. PMID: 11368249 Review.

• Association Between Mycophenolate Mofetil Use and Subsequent Infections Among Hospitalized Patients with Systemic Lupus Erythematosus: A Nested Case-Control Study.

  Guo Q, Zhang X, Sun S, Tang X, Shen W, Liang J, Yao G, Geng L, Ding S, Chen H, Wang H, Hua B, Zhang H, Wang D, Feng X, Sun L, Jin Z. Guo Q, et al. Rheumatol Ther. 2023 Dec;10(6):1535-1554. doi: 10.1007/s40744-023-00595-5. Epub 2023 Sep 24. Rheumatol Ther. 2023. PMID: 37742321 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information